PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
15-Mar-2022 AlzeCure presents new clinical data with ACD856 at Alzheimer's conference AlzeCure Pharma AB
11-Mar-2022 Why Are Energy-Based Aesthetic Devices Becoming Popular in MEA P&S Intelligence
10-Mar-2022 Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B Freeline Therapeutics Holdings plc
10-Mar-2022 Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 Transgene
09-Mar-2022 HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer HUTCHMED
08-Mar-2022 Rapid Microbial Methods, Contamination Control, Sterility Assurance and Environmental Monitoring to be covered at Microbiology East Coast Conference in Boston SMi Group
07-Mar-2022 UK Regulator Cites CluePoints’ Solutions in Updated Guidance CluePoints
05-Mar-2022 Exclusive Chemaxon Interview released - Sponsor at AI in Drug Discovery Conference 2022 SMi Group
03-Mar-2022 Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Sanofi
03-Mar-2022 Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Sanofi
02-Mar-2022 Analyses from NAVIGATOR and PATHWAY trials presented at the 2022 AAAAI Annual Meeting AstraZeneca
02-Mar-2022 Avance Clinical Announces New Office Opening in Sydney Avance Clinical
01-Mar-2022 AARDEX Group Joins Innovative IT4Anxiety Project AARDEX
28-Feb-2022 mdgroup to partner with ERGOMED on new Rare Disease Innovation Center mdgroup
28-Feb-2022 ERGOMED announces launch of its Rare Disease Innovation Center™ ERGOMED
25-Feb-2022 New preclinical tolebrutinib data demonstrated superior brain penetration and potency Sanofi
23-Feb-2022 New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA®▼ (guselkumab) at 12 Weeks Janssen
23-Feb-2022 Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab▼ and Golimumab Combination Therapy Versus Either Monotherapy Alone Janssen
23-Feb-2022 The Majority of Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA®▼ (guselkumab) Janssen
23-Feb-2022 Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program Sanofi